These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 20922572)

  • 1. How do tumors actively escape from host immunosurveillance?
    Wilczyński JR; Duechler M
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):435-48. PubMed ID: 20922572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How do tumor stem cells actively escape from host immunosurveillance?
    Qi Y; Li RM; Kong FM; Li H; Yu JP; Ren XB
    Biochem Biophys Res Commun; 2012 Apr; 420(4):699-703. PubMed ID: 22465008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
    Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
    Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer.
    Gross S; Walden P
    Immunol Lett; 2008 Feb; 116(1):7-14. PubMed ID: 18164076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current concepts of tumor-infiltrating lymphocytes in human malignancies.
    Chiou SH; Sheu BC; Chang WC; Huang SC; Hong-Nerng H
    J Reprod Immunol; 2005 Oct; 67(1-2):35-50. PubMed ID: 16111767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape mechanisms in tumor immunity: an update.
    Müller L; Kiessling R; Rees RC; Pawelec G
    J Environ Pathol Toxicol Oncol; 2002; 21(4):277-330. PubMed ID: 12510961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis.
    Dirkx AE; Oude Egbrink MG; Wagstaff J; Griffioen AW
    J Leukoc Biol; 2006 Dec; 80(6):1183-96. PubMed ID: 16997855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
    Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
    J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
    Salih HR; Nüssler V
    Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer immunotherapy. Importance of overcoming immune suppression].
    Malvicini M; Puchulo G; Matar P; Mazzolini G
    Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capitalizing on the immunogenicity of dying tumor cells.
    Fonseca C; Dranoff G
    Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dormant tumor cells as a therapeutic target?
    Quesnel B
    Cancer Lett; 2008 Aug; 267(1):10-7. PubMed ID: 18384938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Principles of tumor immunosurveillance and implications for immunotherapy.
    Ochsenbein AF
    Cancer Gene Ther; 2002 Dec; 9(12):1043-55. PubMed ID: 12522443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-resident CD8+ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression.
    Egilmez NK; Kilinc MO
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):399-405. PubMed ID: 20872283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.
    ten Hagen TL; Seynhaeve AL; Eggermont AM
    Immunol Rev; 2008 Apr; 222():299-315. PubMed ID: 18364010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
    Poggi A; Zocchi MR
    Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.